ARTICLE

Received 25 Jun 2015 | Accepted 6 Nov 2015 | Published 9 Dec 2015

DOI: 10.1038/ncomms10131

OPEN

Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas

Kui Wu^{1,2,3,4,5,*}, Xin Zhang^{2,3,4,*}, Fuqiang Li^{1,*}, Dakai Xiao^{2,3,6,*}, Yong Hou^{1,5,*}, Shida Zhu^{1,5,*}, Dongbing Liu¹, Xiaofei Ye^{1,7}, Mingzhi Ye^{1,8}, Jie Yang¹, Libin Shao¹, Hui Pan^{2,3,6}, Na Lu¹, Yuan Yu¹, Liping Liu^{2,3,6}, Jin Li^{2,3,6}, Liyan Huang^{2,3}, Hailing Tang^{2,3}, Qihua Deng^{2,3,6}, Yue Zheng¹, Lihua Peng¹, Geng Liu¹, Xia Gu⁹, Ping He⁹, Yingying Gu^{3,9}, Weixuan Lin⁶, Huiming He⁶, Guoyun Xie¹, Han Liang¹, Na An¹, Hui Wang¹, Manuel Teixeira¹⁰, Joana Vieira¹⁰, Wenhua Liang^{2,3,4}, Xin Zhao¹, Zhiyu Peng^{1,8}, Feng Mu^{1,11}, Xiuqing Zhang^{1,8}, Xun Xu¹, Huanming Yang^{1,12}, Karsten Kristiansen^{1,2}, Jian Wang^{1,12}, Nanshan Zhong^{3,4}, Jun Wang^{1,5,**}, Qiang Pan-Hammarström^{1,7,**} & Jianxing He^{2,3,4,**}

The landscape of genetic alterations in lung adenocarcinoma derived from Asian patients is largely uncharacterized. Here we present an integrated genomic and transcriptomic analysis of 335 primary lung adenocarcinomas and 35 corresponding lymph node metastases from Chinese patients. Altogether 13 significantly mutated genes are identified, including the most commonly mutated gene *TP53* and novel mutation targets such as *RHPN2*, *GLI3* and *MRC2*. *TP53* mutations are furthermore significantly enriched in tumours from patients harbouring metastases. Genes regulating cytoskeleton remodelling processes are also frequently altered, especially in metastatic samples, of which the high expression level of *IQGAP3* is identified as a marker for poor prognosis. Our study represents the first large-scale sequencing effort on lung adenocarcinoma in Asian patients and provides a comprehensive mutational landscape for both primary and metastatic tumours. This may thus form a basis for personalized medical care and shed light on the molecular pathogenesis of metastatic lung adenocarcinoma.

¹BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China. ²Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. ³Guangzhou Institute of Respiratory Disease & State Key Laboratory of Respiratory Disease, Guangzhou 510120, China. ⁴National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China. ⁵Department of Biology, University of Copenhagen, DK-2200 Copenhagen N, Denmark. ⁶Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. ⁷Department of Laboratory of Medicine, Karolinska Institutet, Stockholm 14186, Sweden. ⁸Guangzhou Key Laboratory of Cancer Trans-Omics Research, BGI-Guangzhou, Guangzhou 510006, China. ⁹Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. ¹⁰Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal. ¹¹BGI-Wuhan, Wuhan 430075, China. ¹²James D. Watson Institute of Genome Sciences, Zhejiang University, Hangzhou 310058, China. * These authors contributed equally to this work. ** These authors jointly supervised this work. Correspondence and requests for materials should be addressed to J.H. (email: drjianxing.he@gmail.com) or to Q.P.-H. (email: Qiang.Pan-Hammarstrom@ki.se) or to J.W. (email: wangj@genomics.cn).

Lung cancer is the leading cause of cancerous deaths worldwide^{1,2} with two major types: non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC), accounting for ~85% and 15% of all diagnosed lung cancers, respectively³. Lung adenocarcinoma is the most common histological type of NSCLC, resulting in >500,000 deaths globally every year⁴. Despite advances in surgery, molecular subtyping and targeted therapy, prognosis of lung adenocarcinoma remains poor and the reasons for this could be due to: (1) Diagnosis was often made already at a late stage when localized malignant tumours spread to regional and distant tissues³; (2) Lack of known targetable driver genes in approximately half of the diagnosed patients^{5,6}; (3) Complexity of inter- and intra-tumour heterogeneity^{7,8}; and (4) Poor understanding on the mechanism of metastasis development, as well as lack of corresponding treatment.

Previous studies have characterized the genomic landscape of lung adenocarcinomas and identified many potential cancer driver genes^{4,9–11}, of which targeting therapies have been developed for several activated oncogenes such as *EGFR*, *ERBB2* and *BRAF*^{6,12–14} and translocations or fusions involving *ALK*, *ROS1* and *RET*^{15–17}. Most of these studies, however, mainly focused on tumour samples obtained from European or North American patients, and the majority of specimens were collected at early disease stages. Undoubtedly, it is important to have a comprehensive genomic analysis on lung adenocarcinomas from Eastern Asian population when considering its rapidly increasing incidence rate and potential genetic heterogeneity between different ethnic populations. Moreover, genetic characterization of advanced lung adenocarcinomas especially those harbouring corresponding metastases will not only expand the spectrum of potential cancer driver genes involved in lung carcinogenesis, but also improve our knowledge on metastasis formation and further guide diagnosis and therapies for metastatic lung adenocarcinomas. A recent study demonstrated high concordance of recurrent somatic alterations between primary tumours and matched metastases in NSCLCs¹⁸. This initial survey was limited though by focusing on targeted sequencing of 189 cancer-related genes.

Here we performed a comprehensive genetic analysis of 101 Chinese lung adenocarcinomas, as well as 35 corresponding lymph node metastases through multiplatform sequencing. Two hundred and thirty-four primary tumours were furthermore included into this study as an independent validation cohort. In an addition to a number of previously reported lung cancer driver genes, we have identified several novel, potentially oncogenic genes that are significantly mutated in our cohort. Integrative analyses through genomic data furthermore highlight pathways that may play a critical role in driving tumour metastasis. These results provide new insights on the pathogenesis of lung adenocarcinomas and also form a basis for further improvement of clinical management of our patients in the precision medicine era.

Results

Sample description and sequencing statistics. Paired tumours and normal adjacent tissues were obtained from 335 patients that provided written informed consent to carry out genomic studies in accordance with local Institutional Review Boards. All tumour specimens were reviewed by independent pathologists to determine the histological subtype, TNM stage and tumour cellularity (Supplementary Fig. 1). Detailed clinical features were summarized in Table 1 and Supplementary Data 1.

Whole-genome, transcriptome sequencing data were obtained from primary tissues and corresponding lymph node metastases

Table 1 | Clinical feature summary of 335 sequenced lung adenocarcinomas.

	Discovery cohort	Validation cohort	Total	P value
Age at surgery, years				0.4918 [†]
Median	59.2	58.6	58.8	
Range	25.2–81.6	32.4–84.9	25.2–84.9	
Gender				0.1303 [‡]
Male	62 (61.4%)	121 (51.7%)	183 (54.6%)	
Female	39 (38.6%)	113 (48.3%)	152 (45.4%)	
Smoking status				0.3373 [‡]
Smoker	37 (36.6%)	68 (29.1%)	105 (31.3%)	
Non-smoker	58 (57.4%)	141 (60.3%)	199 (59.4%)	
NA	6 (5.9%)	25 (10.7%)	31 (9.3%)	
Follow-up, months				0.1042 [†]
Median	22	37	36	
Range	4–80	1–77	1–80	
Tumour stage				0.1447 [‡]
I	19 (18.8%)	63 (26.9%)	82 (24.5%)	
II	18 (17.8%)	51 (21.8%)	69 (20.6%)	
III	56 (55.4%)	98 (41.9%)	154 (46%)	
IV	8 (7.9%)	21 (9%)	29 (8.7%)	
NA	0 (0%)	1 (0.4%)	1 (0.3%)	
Metastasis				0.1087 [‡]
Negative	25 (24.8%)	80 (34.2%)	105 (31.3%)	
Positive	76 (75.2%)	153 (65.4%)	229 (68.4%)	
NA	0 (0%)	1 (0.4%)	1 (0.3%)	
Survival status				0.3612 [‡]
Alive	67 (66.3%)	160 (68.4%)	227 (67.8%)	
Dead	33 (32.7%)	60 (25.6%)	93 (27.8%)	
NA	1 (1%)	14 (6%)	15 (4.5%)	

NA, not applicable.
[†]Wilcoxon rank sum test.
[‡]Pearson's χ^2 -test.

of 24 Chinese lung adenocarcinoma patients. Genomes were sequenced to a mean depth of $49.6 \times$ (range: $42.0\text{--}57.8 \times$) for primary tumours and $51.2 \times$ ($44.4\text{--}66.3 \times$) for metastatic specimens, while it was $31.9 \times$ (range: $23.6\text{--}34.9 \times$) for adjacent normal tissues. On average 93M clean reads ($73\text{--}110\text{M}$) were generated from whole-transcriptome sequencing. Whole-exome sequencing (WES) was performed on both primary and matched lymph node metastases from an additional 11 cases, and from primary tumour samples from a further group of 66 patients. RNA-seq analysis was furthermore performed in 32 cases from the latter group. Exome sequencing reached median fold coverage of $81.4 \times$ ($37.6\text{--}293.7 \times$) and 37.3M reads ($20.0\text{--}53.4\text{M}$) were generated from RNA-seq (Supplementary Data 2 and 3). These 101 cases constituted the discovery cohort.

For verification, an independent hybrid-recapture and ultra-deep DNA sequencing were performed on a set of 51 selected genes with a mean fold coverage of $140 \times$ ($48.2\text{--}455.1 \times$) on custom target regions in 98 cases of the discovery cohort described above and additional 234 primary lung adenocarcinomas (the validation cohort) (Supplementary Data 4). The cohort description with different data sets was summarized in Supplementary Data 5.

Somatic DNA alterations and verification. Somatic point variations and small insertions/deletions (indels; <50 bp) were detected using MuTect¹⁹ and Platypus²⁰, respectively. A mean of 9.7 somatic mutations per Mb ($1.7\text{--}64.4$) were identified from the first 101 primary lung adenocarcinomas, while the mean somatic

mutation rate in 35 lymph node metastases was 6.4 mutations per Mb (0.8–60.0) (Supplementary Data 6 and 7). A significantly higher mutation rate was observed in smokers (mutations per Mb: mean 14.2, range 2.3–64.4) than in non-smokers (mutation per Mb: mean 7.0, range 1.7–29.2, $P=0.0144$, Wilcoxon rank sum test) for primary tumours, while the mutation rate in metastases was 9.2 (0.8–60.0) versus 4.7 (1.2–12.1) for smokers and non-smokers, respectively.

Identified mutations were verified through two procedures. First, mass spectrum was performed by using the MassArray platform of Sequenom to validate 79 randomly selected mutations, of which 76 (96.2%) were confirmed (Supplementary Data 8). Otherwise, ultra-deep target region sequencing on a set of 51 selected genes was used to validate the mutations identified in 98 primary tumours and 33 metastasis samples. In this analysis, a total of 967 single nucleotide polymorphisms (SNPs) and indels that passed pipeline filters were assayed, of which 960 were successfully verified, achieving a validation rate of 100% and 96% for single nucleotide variants (SNVs) and indel, respectively (Supplementary Data 9).

Mutational signatures of lung adenocarcinomas. The somatic mutation detection in our discovery cohort reveals a consistently higher mutation rate in lung cancer than the other tumour types except malignant melanoma, which links to exposure to ultraviolet light²¹. Mutation spectrum analysis revealed that the most common somatic substitutions in our discovery cohort were C→A transversions and C→T transitions as previously reported for lung adenocarcinomas⁴ (Supplementary Fig. 2). Mutational signatures of 24 cases with whole-genome sequencing (WGS) data were subsequently characterized on both primary and metastatic tumours based on the 96 possible mutation types and were compared with the WGS data derived from previously reported European lung adenocarcinomas⁴. Four highly confident mutational signatures were extracted from each sample set and showed no apparent difference between primary and metastatic samples (signature 1, 2, 3, 4) (Fig. 1). When compared with the four signatures extracted from European lung adenocarcinomas, highest correlation (Pearson Correlation >0.99) was detected in signatures that were predominated by C>A mutations (Chinese signature 1 and European signature 1) and associated with cigarette smoking. The second highly correlated signature was Chinese signature 3 to European signature 3 (Pearson correlation >0.95), which attributed to over-activated members of the APOBEC family of cytidine deaminase. Indeed the expression levels of APOBEC1, APOBEC3B, APOBEC3C and APOBEC3F were found to be significantly higher in both primary and metastatic tumours as compared with normal tissues ($P<0.01$, Supplementary Fig. 3). Similar analysis was also applied to 10 previously reported stage I Chinese lung adenocarcinomas with WGS data²². Three high confident signatures from these tumours were identified, which show high correlation with signature 1, signature 3 and signature 4 that were extracted from 24 Chinese lung adenocarcinomas at late stage and 22 European lung adenocarcinomas. This observation indicated the significant association of these three signatures with lung adenocarcinomas, at both early and late stage of the disease, and they are shared within different ethnic populations. It is notable that signature 2, with transitions and transversions that predominantly occur at ApNpA and TpNpT trinucleotides (Fig. 1), is specific to our cohort that was not found in any of the 30 cancer types reported before²¹ or in early stage lung adenocarcinoma. Furthermore, the metastatic tumours seem to more often (46%, 11/24) carry dominant proportion of ‘signature 2’ (with >20% of contribution) as compared with the primary tumours (25%,

6/24). The contribution of ‘signature 2’ is highly correlated with the proportion of indel mutations, as tumours carried signatures with higher contribution of ‘signature 2’ also harboured significantly higher proportion of indel mutations in all somatic mutations detected (Supplementary Fig. 4a). In contrast, the other signatures do not show such linear association with indel mutation. Since the mutational signature analysis was carried out only using base substitutions, the association of indel mutation of specific signature should not be attributed to incorporation of indel mutations to the analysis. We then verified our finding in the mutation data of 22 European lung adenocarcinomas. We found that the contribution of ‘signature 2’ in these 22 European lung adenocarcinomas is only 4% on average, significantly lower than that in primary tumours (18%) and metastatic tumours (22%) in our sequenced cohort ($P<0.001$, Wilcoxin Signed Ranks Test). This explained that why this signature was not evidently identified from the previous analysis in the European sample set. However, we confirmed that in the European tumours, the contribution of ‘signature 2’ is also highly correlated with the proportion of indel mutations (Supplementary Fig. 4b). No germline or somatic mutations in DNA repair genes including various mismatch repair genes, *BRCA1* and *BRCA2* could explain the occurrence of ‘signature 2’. Although this signature seems to be due to inclusion of large number of late stage of lung adenocarcinoma patients with metastasis in our study, WGS data in a larger cohort of patients will be required to confirm this association and to further understand the underlying mutagenesis mechanism.

Distinct combinations of mutational signatures were observed in each individual cancer, which indicated inter-tumour heterogeneity (Supplementary Fig. 5a). It is interesting that though we identified similar landscape of mutational signatures between primary and metastatic sample sets, about 33% (8/24) cases showed different contribution of signatures between the paired primary and metastatic tumours, which may be attributed to intra-tumour heterogeneity or mutational selection during metastases (Supplementary Fig. 5b). No significant correlation was observed between the mutation signature distribution and patient age, gender, smoking status or tumour purity (Supplementary Data 10), which may be partially due to the limited sample size.

Significantly mutated genes. Given the high level of background mutation rate in lung cancer, oncogenic driver event analysis was carried out through a modified pipeline described previously^{23,24}, which considered the mutation prevalence in the context of the background mutation rate and gene sequence length, as well as evaluation of functional impact. The MutSig²⁵ algorithm was subsequently applied to identify significantly mutated genes and the mutant frequency was calculated by integrating the discovery and validation cohorts, for altogether 335 primary tumours and 35 metastasis specimens. These analyses revealed 13 statistically significant mutated genes ($q<0.1$, Fig. 2a, Supplementary Fig. 6, Supplementary Data 11). The most frequently mutated genes in primary tumours are *TP53* (44%), *EGFR* (39%), *LRP1B* (19%) and *KRAS* (11%), indicating the major contribution of these genes in lung carcinogenesis. The other frequently mutated genes include well-known tumour suppressor genes: *PTPRD* (7%), *STK11* (4%) and *SMAD2* (2%), and oncogenes *PIK3CA* (5%), *BRAF* (4%) and *FLT1* (3%). Consistent with the previous studies, *KRAS* mutations are mutually exclusive with those of *EGFR*, and are more commonly observed in smokers^{4,10,26}. We also confirmed a higher mutation rate of *EGFR* than *KRAS* in our cohort, which is in contrast to that in the Caucasian populations. Notably, 54% (71/132) of the *EGFR* mutations are Leu858Arg, and another 29% (39/132) *EGFR* mutations are exon 19 deletions, which are

Figure 1 | Mutational signatures of lung adenocarcinoma. Comparison of signatures between primary and metastatic lung adenocarcinomas in this study as well as lung adenocarcinomas derived from a previously published European cohort. Signatures were displayed according to the 96-substitution classification, with x-axes showed mutation types and y-axes showed trinucleotide frequency of each mutation type.

sensitive targets of tyrosine kinase inhibitor therapies¹². This confirms the importance of testing these specific mutations for Chinese lung adenocarcinoma patients.

Mutations in *RHPN2* (5%), *GLI3* (4%) and *MRC2* (2%) have not been reported previously as driver genes in lung adenocarcinomas but were recurrently observed in our cohort and are nominated to be significantly mutated. *RHPN2*, which encodes a member of the raphilin family of Ras-homologous (Rho) GTPase-binding proteins, was first identified to interact with RhoA as a downstream effector molecule to regulate the actin cytoskeleton²⁷, a process that is involved in cancer cell migration and invasion. A recent study further demonstrated that *RHPN2* could drive mesenchymal transformation in malignant glioma via triggering RhoA activation²⁸. Notably, a novel but recurrent mutation V73M was identified for *RHPN2* (Supplementary Fig. 6b), which affecting the Rho binding domain, implying that this site could be a potentially functional important hotspot mutation. *GLI3* encodes a zinc-finger transcription factor that modulates the sonic hedgehog (SHH) pathway, and one recent study on NSCLC demonstrated that overexpression of truncated *GLI3* was significantly associated with lymph node metastasis and poor survival²⁹. Another investigation also showed that high expression of *GLI3*, together with *GLI1*, is associated with tumour progression in advanced lung adenocarcinoma³⁰. The exact mechanism of *GLI3* mutations in tumorigenesis and whether the potentially affected SHH signalling could be targeted have not been determined. *MRC2* (also known as uPARAP, Endo180 or CD280), a member of mannose receptor family, is found to be involved in extracellular matrix remodelling by mediating collagen degradation^{31,32}. Functional experiments and clinical surveys have demonstrated that high expression of *MRC2* can promote tumour growth and drive metastasis, results in significantly worse prognosis in several cancers^{33–36}.

Additional recurrently mutated genes that did not reach a statistical significance by MutSig, but may functionally impact carcinogenesis, were also identified. These include *APC* (5%), *KEAP1* (4%), *ATF7IP* (4%), *ITIH5* (3%), *IQGAP3* (3%), *MET* (3%), *ERBB2* (2%) and *TERT* (2%) (Fig. 2a, Supplementary Fig. 6 and Supplementary Data 11), of which *KEAP1* was mutually exclusively mutated with *EGFR*. The mutation frequencies of all the mutated genes described above in metastatic specimens are also shown in Fig. 2a. It is interesting to note that though *KRAS* was frequently mutated in primary tumours, no mutations were called for this gene in the 35 sequenced metastases, including those 5 samples with paired, *KRAS*-mutated primary tumours. The five metastatic tumours with *KRAS* mutations 'loss' were first confirmed as genetically identical with the corresponding primary tumours, by comparing both the pre-sequencing mass spectrometric fingerprint genotyping (Supplementary Data 12) and the genome-wide SNPs called from sequencing data. Visual review of the sequencing reads in these samples subsequently confirmed the sufficient coverage of all mutated sites for high quality mutation calling (Supplementary Data 13). Visual inspection furthermore confirmed that none of the normal tissues carried any reads of the mutated *KRAS* allele. At most two or three reads with mutation can be visualized, however, from metastatic specimens, thus suggesting a significantly lower frequency (0.01 on average; range: 0–0.02) in the metastases as compared with the corresponding primary tumours (0.30 on average; range: 0.18–0.46). Sanger sequencing further showed evident mutant genotype in primary tumours but no peak of altered signal was detected either in normal tissues or metastatic tumours.

The mutation patterns were further correlated with other clinical features such as gender, smoking status, age and

Figure 2 | Somatic mutations and clinical association in lung adenocarcinomas. (a) Recurrently mutated genes and mutant frequencies in the full discovery and validation cohorts, comprising 335 primary tumours and 35 metastatic tumours. Primary tumours were classified into two groups: samples with metastases in adjacent lymph nodes or distant organs on diagnosis or surgery (PM+, $n = 229$), and samples which were metastasis free at the time for diagnosis (PM-, $n = 105$). Gender, smoking status and tumour stages were listed at the bottom according to the samples, as well as mutation types. Asterisks indicate genes predicted to be significantly mutated by MutSig algorithm (FDR < 0.1). **(b)** Associations of specific mutated genes with metastasis status, gender, smoking status and age. Asterisks were marked at the sides of sample sets with significantly higher mutant frequencies ($P < 0.05$, Fisher's exact test).

tumour stage. The *EGFR* mutations were more frequently observed in females, while mutations in *LRP1B*, *KRAS*, *PTPRD*, *APC*, *STK11*, *KEAP1*, *ITIH5* and *FLT1* were significantly enriched in males ($P < 0.05$, Fisher's exact test). While *EGFR* mutations were enriched in non-smokers, mutations of *LRP1B*, *KRAS*, *PTPRD*, *KEAP1* and *GLI3* were significantly enriched in smokers ($P < 0.05$, Fisher's exact test). Notably, *TP53*, *GLI3* and *ITIH5* were significantly more mutated in patients aged > 60 years ($P < 0.05$, Fisher's exact test) but none of the recurrently mutated genes was associated with tumour stage (Fig. 2b).

Metastasis is one of the most critical issues for disease progression in lung adenocarcinoma, however, whether the mutation patterns are different between tumours with or without metastasis is yet to be studied. All the samples were thus classified into two groups, those who had metastases in adjacent lymph nodes or distant organs on diagnosis or surgery (PM+, $n = 229$),

and those who were metastasis free at diagnosis (PM-, $n = 105$). This classification was not associated with gender ($P = 0.64$), smoking status ($P = 0.79$) or age ($P = 0.08$). Fisher's exact test indicated that *TP53* was the only gene that was significantly ($P < 0.05$) enriched in patients harbouring metastases (Fig. 2b), suggesting an important role of this tumour suppressor gene not only in primary tumorigenesis but also in driving the metastatic process.

Kaplan–Meier survival analysis was performed in all patients ($n = 335$) and validation cohort ($n = 234$), respectively, to explore the potential association between the recurrently mutated genes and individual outcome. Individuals harbouring somatic mutations in *TP53*, *LRP1B*, *STK11*, *KEAP1*, *BRAF*, *MET* and *MRC2* had significantly shorter survival time than individuals with wild-type genotypes (Supplementary Fig. 7), which suggested that alterations in these genes could be used as prognostic markers in clinical practice.

Somatic CNVs and mRNA expression profiling. Somatic copy number alterations (SCNAs) were profiled in the 101 primary tumours and 35 metastases from the discovery cohort. The results revealed frequent abnormalities of chromosomal arms involving gain of 1q, 3q, 5p, 7p/q, 8q, 14q, 16p, 17q and 20q, as well as loss of 3p, 4q, 6q, 8p, 9p, 12q, 13q, 15q, 17p and 18q (Supplementary Fig. 8), most of which were consistent with previous results reported in lung adenocarcinomas⁹. GSITIC³⁷ was applied to identify statistically significant recurrent focal copy number variants (CNVs) (Fig. 3a, Supplementary Data 14). Significant somatic amplifications of *NKX2-1*, *TERT*, *EGFR*, *CCND1*, *MDM2*, *CDK4*, *MET*, *MYC* and *MECOM* were observed, as well as deletion of *TP53*, *PTPRD* and *CDKN2A/2B* that have been widely reported in lung adenocarcinoma. Significantly amplified regions that encompassed genes involved in cytoskeleton organization or focal adhesion were also identified, including *IQGAP3*, *TRIO*, *FSCN1/FSCN2* (fascin homologue 1/2, actin-bundling protein),

RAC1/RAC3 and *ITGB4/ITGB8*. Recurrent, novel focal deletion regions were furthermore detected affecting tumour suppressor genes *SMAD2* and *SMAD4*. Profiling of CNAs in metastatic tumours additionally identified amplification of *SOX3* and deleted regions affecting *STK11*, *KEAP1* and *MGA*. It is interesting that CNAs of several genes with function in histone or chromatin modification, such as *KDM5B*, *CREBBP*, *SETD2*, *SMARCA4* and *MECP2* were also found either in primary or metastatic tumours, suggesting a potential role of epigenetic regulation in lung adenocarcinoma. Profiling of mRNA expression status of 56 tumour/adjacent normal pairs confirmed correlated higher expression level in genes with copy number amplification than those with deleted CNAs (Supplementary Fig. 9).

Unsupervised clustering analysis of gene expression data from the 56 primary tumours identified three subgroups (cluster 1, cluster 2 and cluster 3) (Fig. 3b). Kaplan–Meier survival analysis indicated that cluster 3, which has higher frequencies of *KRAS*,

Figure 3 | Genomic copy number alterations and mRNA expression profiling. (a) Landscape of genomic copy number alterations in Chinese lung adenocarcinomas. Amplifications and deletions across chromosome 1–22 and X were shown with y-axis presenting G-score altitude. CNV profiles in primary and metastatic tumours were shown with different colours. Putative cancer driver genes were marked in locations with peaks across the genome. (b) Cluster classification of 56 tumours indicated three clusters with different gene expression pattern, 464 representative genes are included. (c) Gene expression clusters integrated with genomic mutations. Tumours were ordered as three clusters shown in **b**. Alterations of selected genes were shown across clusters, revealing mutations (Mut.) of *KRAS*, *KEAP1*, *FLT1* as well as copy number amplification (Amp.) of *CEP72* were enriched in cluster 3. Cluster 3 was also characterized as having exceeded expression (Expr.) status in genes participating in PI3K–Akt pathway or cytoskeleton remodelling process.

FLT1, *KEAP1* mutations and amplified *CEP72*, demonstrated a significantly shorter survival time than patients in the other two clusters (Supplementary Fig. 10). We also found that several genes participate in the PI3K–Akt pathway or cytoskeleton remodelling process, such as *PIK3CA*, *PKN2*, *PTK2*, *DOCK1*, *SOS1* and *MAPK1* had elevated expression status in cluster 3 as compared with cluster 1 and cluster 2, implying the activation of these processes may direct to disease progression (Fig. 3c).

Identification of structural alterations. Taking advantage of high depth WGS ($50\times$ coverage on tumour samples and $30\times$ coverage for adjacent normal tissues) and corresponding transcriptome sequencing of 24 cases with paired primary and metastasis tumours sequenced, the structural alterations in lung adenocarcinoma were characterized. A total of 2,287 and 1,910 somatic structural aberrations were detected from primary and metastatic tumours, respectively (Supplementary Data 15 and Supplementary Fig. 11). Among the translocation events in primary tumours, 1,404 were inter-chromosomal (CTX), 201 were intra-chromosomal (ITX), 295 were inversions (INV) and 387 were deletions (DEL). The numbers of aberrant events in metastases were 1,467 CTXs, 127 ITXs, 107 INVs and 211 DELs. Well-known fusion genes *EML4-ALK* were identified in 2 out of these 24 cases in both primary and metastatic tumours with supportive evidence from both DNA and RNA data. Further screening through targeted sequencing of all 335 cases revealed 7 additional tumours harbouring this gene–gene fusion, giving an overall 3% alteration rate. Concurrent and mutual exclusion analysis indicated that *EML4-ALK* fusion was mutually exclusive with *EGFR* mutations (Supplementary Fig. 12), consistent with a recent large-scale clinical screening of NSCLC for *EGFR*, *KRAS* mutations and *ALK* rearrangements³⁸. Previously reported rearrangements of *ROS1* and *RET* genes in NSCLC patients were not observed in our patient cohorts.

We further identified additional 13 putative gene–gene fusion events in these 24 metastatic cases using a combination of the whole-genome and transcriptome sequencing data (Supplementary Data 16, Supplementary Fig. 13). It is notable that among these fusions, several genes that function in cytoskeleton regulation were involved, including *IQGAP3*, *EPB41*, *CDC42*, *PARD6G*, *PTK2B* and *KALRN*, suggesting that these alterations may promote metastasis development. Other fused genes with putative role in tumorigenesis or metastasis formation include *CHEK2*, *FGFR2*, *MIIP*, *CPB1*, *EIF4A2*, *MECOM* and *USP32*.

Analysis of the *IQGAP3* locus. Integrated analysis of somatic mutations, CNAs, structural aberrations and gene–gene fusions using multiplatform studies highlighted *IQGAP3* was altered in a notable number of cases. This gene, a member of the IQGAP family that has both IQ motifs and Ras GTPase-activating protein-related domain (GRD)^{39,40}, was altered in 10% of lung adenocarcinomas (discovery cohort, $n=101$), by somatic mutations (three cases), copy number amplification (seven cases) and translocation (one case). Targeted regional sequencing of the validation cohort ($n=234$) further identified eight additional cases harbouring somatic mutations on *IQGAP3*.

Analysis of mRNA expression of 56 RNA sequenced primary tumours and 24 RNA sequenced metastases revealed that *IQGAP3* was expressed at a significantly higher level in tumour specimens than adjacent normal tissues (Supplementary Fig. 14). The *IQGAP3* expression in 132 primary lung adenocarcinomas (61 from discovery cohort and 71 from validation cohort) with available RNA within the 335 sequenced cases was subsequently measured by quantitative reverse transcription–PCR (RT–PCR; Supplementary Data 17), and confirmed the higher expression

level of *IQGAP3* in these tumours (Fig. 4a). An elevated level of *IQGAP3* protein was also confirmed in a subset of primary tumours by immunohistochemical staining ($n=42$, $P<0.001$, Wilcoxin Signed Ranks Test, Supplementary Fig. 15). Kaplan–Meier analysis indicated that patients with a higher level of *IQGAP3* mRNA had significantly shorter overall survival and disease-free survival (Fig. 4a, Supplementary Fig. 16). Furthermore, Multivariate Cox proportional hazard analysis showed that

Figure 4 | Integrated characterizations of *IQGAP3* alterations. (a) Quantitative RT–PCR analysis of 132 lung adenocarcinoma patients showed significantly higher expression of *IQGAP3* mRNA in tumours than in adjacent normal tissues in lung adenocarcinoma patients. Kaplan–Meier survival curves showed that patients with high *IQGAP3* expression had shorter overall survival. (b) Three-dimensional model of *IQGAP3* protein showing the somatic mutations affecting functional domains. qPCR analysis in patients harbouring these mutations showed no significant difference of *IQGAP3* expression between tumour and normal tissues. (c) Tumours harbouring genomic amplifications of *IQGAP3* in chromosome 1. QPCR analysis indicated higher expression of *IQGAP3* in corresponding tumours with copy gain of *IQGAP3* than in adjacent normal tissues.

a higher level of IQGAP3 was an independent risk factor for poor prognosis of the lung adenocarcinoma patients (Supplementary Data 18 and 19, hazard ratio = 2.28, 95% confidence interval = 1.25–4.14, $P = 0.007$).

The association of IQGAP3 genetic alterations and mRNA expression was subsequently investigated. No significant difference was observed in IQGAP3 expression between tumours and normal tissues in the eight cases carrying somatic mutations, including four mutated sites located in the Ras GTPase-Activating Protein (RasGAP) domain (Q1085H, A1124T, D1164E and L1292 splicing site) and one truncated mutation that resulted in the loss of the RasGAP C terminus domain (Fig. 4b). Furthermore, patients harbouring IQGAP3 SNVs showed better survival status than the other cases though did not reach a statistical significance (Supplementary Fig. 7). By contrast, this gene was overexpressed in tumours affected by copy number amplifications (Fig. 4c). An inter-chromosomal rearrangement occurred between chromosome 17 and chromosome 1 was identified in patient WG04, in both primary and metastasis tumours, which results in a novel gene–gene fusion involving *TMC6* and *IQGAP3*, with reversed 5' and 3' orientation (Supplementary Fig. 17a). The fused product consists of exons coding most of the RasGAP domain and the intact RasGAP C terminus domain of IQGAP3, while retained exon 1 and exon 2 of *TMC6*. RNA-seq data revealed markedly higher, outlier expression of IQGAP3 in primary and metastasis tumour of patient WG04, and investigation of reads coverage indicated that highly covered regions were enriched in exons containing RasGAP and RasGAP C terminus domains (Supplementary Fig. 17b,c).

Altered key pathways and therapeutic targeting. Integrative analysis of altered key pathways affected by somatic mutations, CNAs as well as frequent rearrangements was performed to construct a comprehensive view of aberrant characteristics for lung adenocarcinoma (Fig. 5a). The most frequently altered pathways in primary tumours were p53 signalling and cell cycle process, affecting 87% of primary tumours and 89% of metastatic tumours. A majority of the observed mutations were somatic mutations in *TP53*, amplifications of *MDM2*, *MYC*, *CCND1*, *CCNE2*, *CDK4* and *CDK6*, as well as loss-of-function variants including deletions of *CDKN2A*, *CDKN2B*, mutations and deletions affecting *SMAD2* and *SMAD4*, of which *TP53* mutations were mutually exclusive with *MDM2* amplification (Supplementary Fig. 12). *CHEK2*, a serine/threonine-protein kinase involved in regulating cell cycle arrest, was altered either by somatic mutation, deletion or rearrangement. The RTK/Ras/PI3K pathway was also frequently altered in lung adenocarcinoma, with 88% of primary tumours and 80% of metastasis tumours in this study harbouring aberrations in genes involved in this pathway. Included were events affecting several therapeutic targets that were responsive to antibodies or kinase inhibitors, such as alterations of *EGFR*, *PIK3CA*, *ALK*, *ERBB2*, *MET*, *AKT1* and *mTOR* (Fig. 6).

Specifically, an additional pathway that involves actin cytoskeleton remodelling and focal adhesion was frequently altered in lung adenocarcinoma, affecting 50% of primary tumours. In addition to IQGAP3, five other genes with important roles in cytoskeleton remodelling exhibited somatic mutations or copy number amplifications, namely, *RHPN2*, *RAC1*, *RAC3*, *TRIO* and *CDC42*. *FSCN1* and *FSCN2* were found to be frequently amplified in our studied cohort. These two genes belong to the Fascin protein family, which organizes F-actin into parallel bundles and plays an important role in cell migration, motility, adhesion and cellular interactions. Several studies have demonstrated a

modulating function of Fascin proteins, especially *FSCN1* in tumour metastasis and considered the overexpression of this gene as a prognostic marker for aggressiveness in carcinomas^{41–43}. Network analysis further extended the interactive association between genes and pathways (Fig. 5b) that promote regulation of cytoskeleton remodelling. It is notable that this process was more frequently in metastasis samples (77%) than primary tumours (50%), implying the potential crucial contributions of these genes in driving metastasis.

Discussion

Although lung adenocarcinoma is one of the most well-studied cancers worldwide, the accuracy of diagnostic and therapeutic effectiveness are far from satisfactory, especially for patients harbouring metastases. In the present study, we carried out a comprehensive genetic characterization of 335 lung adenocarcinomas by integrating WGS, WES and RNA-seq. Sixty-eight per cent of studied cases were metastasis positive, providing an opportunity for the investigation of potential mechanisms and identifying biomarkers for driving metastasis.

Our study first delineated the similarity and distinctive mutational features of lung adenocarcinomas between Chinese and Caucasians. We discovered signatures associated with smoking and activation of APOBEC molecules that were shared in tumours from both ethnic populations and also detected signature specific to our cohort, which consists mainly late stage lung adenocarcinomas and is associated with the proportion of indel mutations. *EGFR* was mutated at a much higher frequency in our cohort than in Caucasians, with a dominance of the Leu858Arg change. By contrast, *KRAS*, the second most commonly mutated gene in Caucasians, was only found in 11% of Chinese patients. Notably, we observed significantly lower frequency or even loss of *KRAS* mutation in the metastatic tumours as compared with their paired primary tumours. The discordance of *KRAS* mutations in primary tumours and corresponding metastases has been noted previously in a few cases of lung adenocarcinomas^{44,45}. Independent studies demonstrated that oncogenic *KRAS* itself initiates the growth of non-invasive tumours in mouse models of lung cancer^{46,47}, implying that *KRAS* mutations may induce tumorigenesis, but might not be responsible for tumour metastasis, at least in some cases. Alternative interpretation of such discordant observation could attribute to tumoral heterogeneity, thus analysis of more biopsies from both primary tumour and metastatic lymph nodes from the same individuals may give a more complete picture⁴⁸. Our results suggest that alterations in major cancer drivers may change during tumour evolution and the development of metastasis, which should be important in clinical application, for instance, it may not be sufficient to determine therapeutic strategy for metastatic tumours base solely on the mutation spectrum in primary tumours.

We identified three genes, *RHPN2*, *GLI3* and *MRC2* to be significantly mutated in our studied cohort. These genes are altered in lower frequency, therefore are not determined as driver genes in lung adenocarcinoma previously. According to the saturation analysis by Lawrence *et al.*⁴⁹, the discovery of candidate cancer genes is significantly associated with the sample set used and taking lung adenocarcinoma as an example ~2,000 cases are required to achieve a comprehensive catalogue of cancer genes with sufficient statistic power when the genes are mutated in >3% of patients. Our discovery of novel significantly mutated genes in lung adenocarcinoma confirms the necessity of continuous sequencing and analysis effort on more tumour-normal pairs of cancer patients. Although our study presented the potential association of these mutations to lung adenocarcinoma

b

Networks (focus on cytoskeleton remodeling)

Figure 5 | Altered pathways and network in lung adenocarcinomas. (a) Somatic mutations, copy number alterations and genomic rearrangements affecting p53 signalling/cell cycle process, RTK/Ras/PI3K pathway, cytoskeleton remodelling regulation and histone/chromatin modification. Percentage presented alteration frequencies in 101 primary tumours and 35 metastatic tumours, respectively. **(b)** Network connection of genes involved in cytoskeleton remodelling regulation. Gene-gene interactions are inferred by CytoScape program.

through bioinformatic exploratory analysis, functional study is essential to demonstrate the exact mechanism of these mutated genes in lung adenocarcinoma carcinogenesis in the future.

We also showed a significant enrichment of *TP53* mutations in patients with metastases on diagnosis or surgery. *TP53* was in fact the most frequently mutated gene in many types of cancers.

Figure 6 | Therapeutic targeting in lung adenocarcinomas. Somatic mutations, copy number alterations and translocations affecting genes that are regarded as targets of specific antibodies or kinase inhibitors. Somatic mutations only consist of recurrent mutations in this cohort or mutations previously reported in the COSMIC database. Primary tumours and metastatic tumours with at least one alteration are shown.

Emerging evidence indicates that mutant TP53 not only loses its tumour-suppressing activity, but also can gain functions that contribute to tumour progression^{50–53}. Many mutations of *TP53* have been implicated in invasion, migration and metastasis in different tumour types (summarized in ref. 54).

Integrative pathway investigation revealed that the most commonly altered processes are related to p53 signalling/cell cycle progression and the RTK/Ras/PI3K (mTOR) pathways in lung adenocarcinoma. Within this group of molecules are several targets for kinase inhibitors that are successfully used for treatment of patients with sensitive mutations. Furthermore, the actin cytoskeleton remodelling process, along with genes involved in focal adhesion was observed to be frequently altered in lung adenocarcinoma. Among the mutated genes involved in cytoskeleton remodelling, *IQGAP3* was highlighted as numerous different alterations were identified including a novel fusion event. Clinical association analysis indicated that a high level of *IQGAP3* expression is a putative biomarker in disease progression and poor survival status, implicating *IQGAP3* as a potentially targetable gene for novel therapeutic strategies. Overall our study provided the first comprehensive description of mutational landscape of lung adenocarcinoma in Chinese patients, defined potential mechanisms for cancer metastasis and provided a basis for effective personalized therapies for this lethal cancer. Whether the discovered novel genomic changes are specific for Asian population and/or represent the disease heterogeneity, remains to be further explored in larger sets of tumour samples.

Methods

Patients and clinical samples description. The primary tumour specimens, adjacent normal tissues and lymph node metastases (if available) were obtained from 335 patients with lung adenocarcinoma who underwent surgical resection in Department of thoracic surgery, the First Affiliated Hospital of Guangzhou Medical University. None of the patients were subjected to chemotherapy or radiotherapy before surgery. Tumours and adjacent normal tissues were frozen in liquid nitrogen and stored at -80°C for further research. The tumour specimens were reviewed by two pathologists independently to determine the histological subtype, TNM stage and tumour cellularity. The primary tumour tissues containing at least 50% of tumour cells and the lymph node metastases with at least 30% of tumour cells were included in this study. Detailed clinical characteristics were summarized in Table 1 and Supplementary Data 1. The routine follow-up was conducted every 3 months and the median follow-up was 36 months. About 227 patients (68%) were alive at the time of last follow-up. This study was approved by the Institutional Review Board of the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. All patients who participated in this study provided written informed consent.

Genomic DNA and total RNA preparation. The genomic DNA from tissues was prepared using the QIAamp DNA Mini Kit (Qiagen) following the manufacturer's instructions. The total RNA was prepared using TRIzol Reagents (Life Technologies). The quantity and quality of DNA/RNA were determined by agarose gel electrophoresis or Agilent 2100 analyzer. Mass spectrometric fingerprint genotyping of 21 common SNPs was performed for all the samples

before sequencing, to verify that paired tumour (primary and metastatic) and normal tissues were derived from the same patient.

Whole-genome and WES. Prior to the library construction, 2–3 μg of genomic DNA from each sample was fragmented using a Covaris sonication system to mean sizes of ~ 500 bp. After fragmentation, libraries were constructed according to the Illumina Paired-End protocol. Briefly, the purified, randomly fragmented DNA was treated with a mix of T4 DNA polymerase, Klenow fragments, T4 polynucleotide kinase and a nucleotide triphosphate mix to repair the ends by blunting and phosphorylation. The blunted DNA fragments were subsequently 3'-adenylated using the Klenow fragment (3'-5' exo) and ligated by T4 DNA ligase to BGI-designed PE Index Adaptors that had been synthesized with 5'-methylcytosine in place of cytosine. After each step, the DNA was purified using the QIAquick PCR Purification Kit (Qiagen). For exome sequencing, 3 μg genomic DNA from each sample was fragmented and ligated PE Index Adaptors then captured with SureSelect Human All Exon 50 Mb Kit as described in the protocol for the SureSelect Target Enrichment System for an Illumina Paired-End Sequencing Library. All the constructed libraries were sequenced on HiSeq 2000 platform using 2×100 -bp paired-end reads.

After removing sequencing reads containing adaptor sequence and low-quality reads, which have too many Ns ($> 10\%$) and low-quality base ($> 50\%$ bases with quality < 5), the high quality paired-end reads were gapped aligned to the UCSC human reference genome (hg19) using BWA⁵⁵. After the processes of fixing mate information, adding read group information, Picard (v1.54) (<http://picard.sourceforge.net/>) was used to mark duplicate reads caused by PCR. Then local realignment of the BWA aligned reads was carried out by using the Genome Analysis Toolkit (GATK)⁵⁶.

After fundamental analysis, the potential somatic substitutions were identified by Mutect¹⁹ with default parameter based on paired alignment files (primary and normal, metastasis and normal). The raw lists of somatic indels were detected by Platypus²⁰ based on default parameter. After this process, germline variants could be effectively removed.

The Somatic CNVs of sample pairs with WGS were identified by modified-method based on Segseq algorithm and copy number gain or loss status using thresholds of ≥ 2.5 copies for gain and ≤ 1.5 copies for loss. The somatic CNVs of sample pairs with WES were identified by the CONTRA⁵⁷ algorithm. In the CONTRA algorithm, base-level log-ratios between the case and control were taken into consideration to eliminated GC bias and imbalanced library size effect. Target regions of < 10 bp with depth of coverage < 10 were discarded. For the remaining regions, the mean log-ratio was calculated and the significant P value was then assigned. Then the circular binary segmentation was applied to the log-ratios of regions with default settings. Segmentation results were then used for the subsequent analysis. GISTIC³⁷ algorithm was used to infer recurrently amplified or deleted genomic regions, using copy numbers in 100-kb windows. G scores represented the frequency and amplitude of amplifications or deletions of each genomic region.

Somatic SVs were identified by a modified pipeline developed based on CREST⁵⁸ algorithm. All the detected variants were subsequently annotated by ANNOVAR⁵⁹.

Validation of somatic mutations. Identified mutations were validated either by mass spectrum or target region captured resequencing. For mass spectrum validation, specific primers were designed for PCR amplification and base extension that covered the mutation sites. Genotyping assay and base calling of successfully amplified products were performed on the MassArray platform of Sequenom. Ultra-deep target region sequencing on a set of 51 selected genes was used to evaluate the validation status of identified SNPs and indels. One microgram of genomic DNA from each sample for validation was used for hybrid capture and library construction. Libraries were then sequenced on HiSeq 2500 platform using 2×100 bp paired-end reads sequencing.

Mutational signature analysis. Mutational signature analysis was performed as follows: briefly, the computational framework for mutational signatures deciphering was downloaded from <http://www.mathworks.com/matlabcentral/fileexchange/38724>. Mutational signatures were extracted from the WGS data of 24 primary tumours and corresponding metastasis tumours as follow: (1) Somatic base substitutions of each data set were classified into 96 possible mutated trinucleotides, as 6 types of substitution (C:G>A:T, C:G>G:C, C:G>T:A, T:A>A:T, T:A>C:G and T:A>G:C) $\times$ 4 types of 5' base (A, C, G, T) $\times$ 4 types of 3' base (A, C, G, T), to generate mutational catalogue. Then the prevalence of somatic mutations was calculated for each type of substitution. (2) Signatures of 15 mutational processes from the mutational catalogue were deciphered by the mutational signature framework. The number of signature extracted (N) is determined by estimating the signature reproducibility and reconstruction error rate and as described by Alexandrov *et al.*⁶⁰, N here is the number where the lowest reconstruction error is achieved without decreasing the reproducibility. (3) The minimal set of mutational signatures was then determined to optimally explain the proportion of each mutation type found in the catalogue, based on reproducibility of their signatures and low error for reconstructing the original catalogue. Somatic mutations of WGS from 22 European lung adenocarcinomas were downloaded from <ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl>. Pearson correlation analysis was performed to compare signature patterns between primary and metastasis tumours in this study and those of European lung adenocarcinomas. Contributions of distinct signatures in individual tumour were also profiled and Pearson correlation analysis was performed to compare the signature contributions between paired primary and metastasis tumours^{21,60}.

Identification of potential significantly mutated genes. Considering the high background mutation rate in lung adenocarcinoma, analysis of significance of mutated genes was performed through two statistical procedures. First, a cancer driver gene prediction model²³ was used to calculate the significance of detected mutations for each mutated gene. The mutation prevalence and functional impact was evaluated by this approach, and a background distribution of mutation score was assigned to each gene then. Taking together the background distribution of mutation score and test statistics of observed mutation scores across samples, a P value was computed for each gene and adjusted using the Benjamini–Hochberg method to further determine the false discovery rate (FDR). Only genes with FDR (q -value) < 0.1 were selected for following analysis. A subsequent prediction of significantly mutated genes was performed using the MutSig²⁵ algorithm and genes with FDR q -value < 0.1 were regarded as significant.

Transcriptome sequencing. About 20 μ g total RNA from each sample was treated with RNase-free DNase I for 30 min at 37 °C (New England BioLabs) to remove residual DNA. Beads with oligo (dT) were used to isolate poly (A) mRNA. First-strand complementary DNA (cDNA) was synthesized using random hexamer-primer and reverse transcriptase (Invitrogen). The second-strand cDNA was synthesized using RNase H (Invitrogen) and DNA polymerase I (New England BioLabs). Then the cDNA libraries were prepared following the manufacturer's instructions and were sequenced on the HiSeq 2000 platform.

The raw reads filtering process include three criteria: (1) Remove reads with sequence adaptors; (2) Remove reads in which unknown bases are $> 10\%$; (3) Remove low-quality reads, which have $> 50\%$ in one read. All subsequent analyses were based on clean reads.

Mapping clean reads to the human genome and transcriptome, the reference sequences used were genome and transcriptome sequences downloaded from the UCSC website (version hg19). The Clean data were respectively aligned to the reference genome and transcriptome by SOAP2. Less than five mismatches were allowed for each read in the alignment.

The gene expression level is calculated by using RPKM method (reads per kb transcriptome per million mapped reads), and the formula is shown as follows:

$$\text{RPKM} = \frac{10^6 C}{NL/10^3} \quad (1)$$

In which C is the number of reads that are uniquely mapped to the given gene, N stands for the total number of reads that are uniquely aligned to all genes and L is the total length of exons from the given gene.

Identification and validation of fusion genes. Soapfuse⁶¹ was used to identify fusion genes between paired tumour and normal samples from transcriptome sequencing using the default parameters. Reads were mapped against the human reference genome sequence (hg19) and annotated transcript. SOAPfuse then detected two kinds of reads to identify potential fusion events: span-reads that were defined as paired-end reads mapping to two distinct genes and junction reads that covered the exact junction sites, after filtering duplicated reads a candidate fusion event was determined if more than two reads support the paired-end connection and junction site. WGS data of samples harbouring fusion genes were also analysed to confirm fusion events that were generated by genomic rearrangements with breakpoints in intron or exon regions. Confirmed fusion events were validated at both RNA and DNA level by PCR and Sanger sequencing.

Concurrence and mutual exclusion analysis. Concurrence and mutual exclusion analysis was performed on significantly mutated genes, significant copy number variations and translocations or fusion events involving *ALK*, as well as clinical features such as smoking, age and metastasis status. Significance was calculated by Fisher's exact test.

Pathway and network analysis. Pathway enrichment analysis was carried out by using WebGestalt⁶² to investigate the distribution of genes affected by somatic mutations, CNAs and genomic rearrangements within the KEGG database. To inquire the potential interaction network of altered genes, Cytoscape (V3.1.1) software⁶³ (<http://www.cytoscape.org/>) was used to identify pathways and network patterns related to cancer through the reactome functional interaction plugin⁶⁴.

Real-time RT-PCR assay. Total RNAs of lung cancer cells and lung adenocarcinoma specimens were extracted using Trizol reagent (Invitrogen). The quality and quantity of RNA were determined by agarose gel electrophoresis and photospectrometry. One microgram of RNA was used for cDNA synthesis using the RT System (Promega) according to the manufacturer's instructions. Real-time PCR was performed using GoTaq qPCR Master Mix (Promega). Thermal cycling conditions were as follow: 1 step for 10 min at 95 °C followed by 40 cycles at 95 °C for 15 s and at 60 °C for 1 min. The quality of the PCR products was monitored using post-PCR melting curve analysis. Relative mRNA levels were calculated with $\Delta\Delta C_t$ methods using β -actin for normalization.

Immunohistochemistry. Immunohistochemistry analysis of IQGAP3 in the primary tumours of lung adenocarcinoma was carried out using a standard avidin–biotin–peroxidase technique. In brief, the formalin-fixed, paraffin-embedded tissue sections were deparaffinized and rehydrated through xylene, graded ethanol and water.

The endogenous peroxidase activity was blocked by incubating the sections in 3% hydrogen peroxide for 15 min, and heat-induced epitope retrieval was performed by incubating the sections in boiling sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6.0) for 20 min in microwave. Then the sections were blocked with 10% normal goat serum in PBS for 10 min at room temperature, and incubated with primary antibody against IQGAP3 (1:80, ab151437, Abcam, USA) diluted in 1% BSA (Zhongshanjinjiao, Beijing, China) overnight at 4 °C. The Maixin Detection System Peroxidase/DAB, Rabbit/Mouse kit was applied to determine immunoreactivity according to the manufacturer's instructions, with 1:50 dilutions of DAB Chromogen to HRP Substrate Buffer. Sections were then washed, and counterstained for 30 s in filtered Harris Haematoxylin (Zhongshanjinjiao). After washing with PBS and dehydration with graded ethanol followed by xylene, the sections were mounted in neutral balsam (Zhongshanjinjiao). The slides were viewed and images were captured using Nikon Eclipse 80i microscope with NIS-Elements F software. Analysis of cytoplasm staining was performed by two pathologists independently through measuring the percentage of positively stained tumour cells. A consensus was reached for intensity by taking the mean if scores were within 20% of each other; otherwise, images were reviewed and a consensus reached.

Statistical analysis for clinicopathological data. The correlation of IQGAP3 expression with clinicopathological characteristics was determined by Pearson's χ^2 -test. The differences of IQGAP3 mRNA and protein between tumours and normal tissues were tested by student's t -test and Wilcoxon signed rank test, respectively. Overall survival and disease-free survival were estimated using Kaplan–Meier method with log rank test. The prognostic significance of IQGAP3 was evaluated by Cox regression model with forward likelihood ratio (LR) method. All statistical analyses were performed using GraphPad Prism 5 and SPSS16.0.

References

- Jemal, A. *et al.* Global cancer statistics. *CA Cancer J. Clin.* **61**, 69–90 (2011).
- Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. *CA Cancer J. Clin.* **63**, 11–30 (2013).
- Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. *N. Engl. J. Med.* **359**, 1367–1380 (2008).
- Imielinski, M. *et al.* Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* **150**, 1107–1120 (2012).
- Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol.* **12**, 175–180 (2011).
- Pao, W. & Hutchinson, K. E. Chipping away at the lung cancer genome. *Nat. Med.* **18**, 349–351 (2012).
- Zhang, J. *et al.* Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. *Science* **346**, 256–259 (2014).
- de Bruin, E. C. *et al.* Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. *Science* **346**, 251–256 (2014).
- Weir, B. A. *et al.* Characterizing the cancer genome in lung adenocarcinoma. *Nature* **450**, 893–898 (2007).

10. Ding, L. *et al.* Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* **455**, 1069–1075 (2008).
11. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* **511**, 543–550 (2014).
12. Paez, J. G. *et al.* EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* **304**, 1497–1500 (2004).
13. Greulich, H. *et al.* Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. *Proc. Natl Acad. Sci. USA* **109**, 14476–14481 (2012).
14. Ballantyne, A. D. & Garnock-Jones, K. P. Dabrafenib: first global approval. *Drugs* **73**, 1367–1376 (2013).
15. Kwak, E. L. *et al.* Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N. Engl. J. Med.* **363**, 1693–1703 (2010).
16. Bergeth, K. *et al.* ROS1 rearrangements define a unique molecular class of lung cancers. *J. Clin. Oncol.* **30**, 863–870 (2012).
17. Drilon, A. *et al.* Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov.* **3**, 630–635 (2013).
18. Vignot, S. *et al.* Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumour and metastases from patients with non-small-cell lung cancer. *J. Clin. Oncol.* **31**, 2167–2172 (2013).
19. Cibulskis, K. *et al.* Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* **31**, 213–219 (2013).
20. Rimmer, A. *et al.* Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. *Nat. Genet.* **46**, 912–918 (2014).
21. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415–421 (2013).
22. Zhao, Y. *et al.* Identification of somatic alterations in stage I lung adenocarcinomas by next-generation sequencing. *Genes Chromosomes Cancer* **53**, 289–298 (2014).
23. Youn, A. & Simon, R. Identifying cancer driver genes in tumour genome sequencing studies. *Bioinformatics* **27**, 175–181 (2011).
24. Kan, Z. *et al.* Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. *Genome Res.* **23**, 1422–1433 (2013).
25. Lawrence, M. S. *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* **499**, 214–218 (2013).
26. Pao, W. *et al.* KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med.* **2**, e17 (2005).
27. Peck, J. W., Oberst, M., Bouker, K. B., Bowden, E. & Burdello, P. D. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization. *J. Biol. Chem.* **277**, 43924–43932 (2002).
28. Danussi, C. *et al.* RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. *Cancer Res.* **73**, 5140–5150 (2013).
29. Bai, X. Y. *et al.* High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer. *Cancer Biomark.* **13**, 37–47 (2013).
30. Ishikawa, M. *et al.* Expression of the GLI family genes is associated with tumour progression in advanced lung adenocarcinoma. *World J. Surg. Oncol.* **12**, 253 (2014).
31. Behrendt, N. *et al.* A urokinase receptor-associated protein with specific collagen binding properties. *J. Biol. Chem.* **275**, 1993–2002 (2000).
32. Curino, A. C. *et al.* Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. *J. Cell Biol.* **169**, 977–985 (2005).
33. Wienke, D. *et al.* The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumour cells and promotes tumour growth *in vivo*. *Cancer Res.* **67**, 10230–10240 (2007).
34. Takahashi, S. *et al.* Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells. *J. Neurooncol.* **103**, 267–276 (2011).
35. Gai, X., Tu, K., Lu, Z. & Zheng, X. MRC2 expression correlates with TGFβ1 and survival in hepatocellular carcinoma. *Int. J. Mol. Sci.* **15**, 15011–15025 (2014).
36. Rodriguez-Teja, M. *et al.* Survival outcome and EMT suppression mediated by a lectin domain interaction of endo180 and CD147. *Mol. Cancer Res.* **13**, 538–547 (2015).
37. Beroukhim, R. *et al.* Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proc. Natl Acad. Sci. USA* **104**, 20007–20012 (2007).
38. Gainor, J. F. *et al.* ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin. Cancer Res.* **19**, 4273–4281 (2013).
39. Briggs, M. W. & Sacks, D. B. IQGAP proteins are integral components of cytoskeletal regulation. *EMBO Rep.* **4**, 571–574 (2003).
40. White, C. D., Brown, M. D. & Sacks, D. B. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. *FEBS Lett.* **583**, 1817–1824 (2009).
41. Tan, V. Y., Lewis, S. J., Adams, J. C. & Martin, R. M. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. *BMC Med.* **11**, 52 (2013).
42. Park, S. H. *et al.* Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. *Int. J. Oncol.* **44**, 637–646 (2014).
43. Al-Alwan, M. *et al.* Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. *PLoS ONE* **6**, e27339 (2011).
44. Schmid, K. *et al.* EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. *Clin. Cancer Res.* **15**, 4554–4560 (2009).
45. Monaco, S. E. *et al.* A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. *Hum. Pathol.* **41**, 94–102 (2010).
46. Jackson, E. L. *et al.* Analysis of lung tumour initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev.* **15**, 3243–3248 (2001).
47. Meuwissen, R., Linn, S. C., van der Valk, M., Mooi, W. J. & Berns, A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. *Oncogene* **20**, 6551–6558 (2001).
48. Baldus, S. E. *et al.* Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. *Clin. Cancer Res.* **16**, 790–799 (2010).
49. Lawrence, M. S. *et al.* Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**, 495–501 (2014).
50. Adorno, M. *et al.* A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. *Cell* **137**, 87–98 (2009).
51. Muller, P. A. *et al.* Mutant p53 drives invasion by promoting integrin recycling. *Cell* **139**, 1327–1341 (2009).
52. Morton, J. P. *et al.* Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. *Proc. Natl Acad. Sci. USA* **107**, 246–251 (2010).
53. Weissmueller, S. *et al.* Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signalling. *Cell* **157**, 382–394 (2014).
54. Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell* **25**, 304–317 (2014).
55. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
56. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
57. Li, J. *et al.* CONTRA: copy number analysis for targeted resequencing. *Bioinformatics* **28**, 1307–1313 (2012).
58. Wang, J. *et al.* CREST maps somatic structural variation in cancer genomes with base-pair resolution. *Nat. Methods* **8**, 652–654 (2011).
59. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
60. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. *Cell Rep.* **3**, 246–259 (2013).
61. Jia, W. *et al.* SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data. *Genome Biol.* **14**, R12 (2013).
62. Zhang, B., Kirov, S. & Snoddy, J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. *Nucleic Acids Res.* **33**, W741–W748 (2005).
63. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
64. Croft, D. *et al.* Reactome: a database of reactions, pathways and biological processes. *Nucleic Acids Res.* **39**, D691–D697 (2011).

Acknowledgements

We appreciate all of the patients and families that contributed to this study. This work was supported by grants of Chinese 863 Program (No. 2012AA02A201, 2012AA02A502), Guangdong Innovative Research Team Program (NO. 2009010016), the Guangdong Enterprise Key Laboratory of Human Disease Genomics, Guangzhou Key Laboratory of Cancer Trans-Omics Research (GZ2012, NO348), the Shenzhen Municipal Government of China (CXB201108250094A, CXB201108250096A), Guangzhou Health-Medical Collaborative Innovation Project (NO. 201400000001-2), Guangdong Ming-Yi Medical Charity Foundation and the Swedish Cancer Society, the Swedish Research Council and the European Research Council (242551-ImmunoSwitch). We also thank M. Dean and L. Goodman for scientific editing.

Author contributions

J.H., Q.P.-H. and Jun W. conceived and managed the research. Xin Z., H.T. and H.P. contributed samples and clinical information. Xin Z. and H.T. prepared DNA and RNA for sequencing. X.G., P.H. and Y.G. performed pathological evaluation for all the clinical samples. Y.H., S.Z., X.Y. and Y.Y. carried out sequencing. Y.H., S.Z. and K.W. designed the bioinformatics analysis. F.L., J.Y., N.L. and G.L. analysed the whole-genome

sequencing data. D.L., L.S., X.Y., N.A. and H.W. analysed the whole-exome sequencing data. D.L., F.L., J.Y. and N.L. analysed the mRNA data. F.L. performed mutational signature analysis. F.L., D.L., N.L., Y.H. and S.Z. performed significantly mutated gene, copy number alteration, translocation and fusion analyses. K.W. and N.L. performed pathway and network analyses. D.X. and L.P. performed clinical association analysis. M.Y., L.L. and J.L. provided assistance in genomic data analysis. D.X. designed the functional experiments. L.H., W.L., H.H., M.T. and J.V. carried out the functional experiments. Q.D. performed immunohistochemistry analysis. F.L., D.L., K.W., N.L., L.P., H.L., Y.Z. and G.X. constructed the figures and tables. Y.H., S.Z. and X.Y. contributed bioinformatics support and scientific advice. M.Y. and Z.P. provided administration assistance. F.M., Xiuqing Z., X.X., H.Y., K.K., Jian W. and N.Z. provided organizational support. K.W. wrote the manuscript. Q.P.-H., K.W., D.X., Y.H. and S.Z. revised the manuscript.

Additional information

Accession code: All the sequencing data of 335 lung adenocarcinomas have been deposited at the European Genome-phenome Archive (EGA, <http://www.ebi.ac.uk/ega/>), which is hosted by the EBI, under the accession code EGAS00001000982.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Wu, K. *et al.* Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. *Nat. Commun.* 6:10131 doi: 10.1038/ncomms10131 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>